Amberstone Biosciences, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Amberstone Biosciences, Inc. - overview
Established
2018
Location
Laguna Hills, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2018 by CEO George Wu, Amberstone Biosciences, Inc. discovers therapeutic antibodies to treat solid tumor cancers and other diseases. In January 2022, Amberstone Biosciences, Inc. raised USD 12 million in a Series A funding co-led by Co-Win Ventures, Sinovation Ventures, and Viva BioInnovator, with participation from Changrong Capital and Lifespan Investments.
Amberstone Biosciences, Inc. develops intramural antibody programs and advances its biopharmaceutical partners’ immunotherapy pipelines. The company uses AmberFlow, a single cell platform that enables decidedly efficient isolation of antibody-drug candidates. In addition, Amberstone Biosciences, Inc.
is developing immunotherapeutic pipeline assets. Amberstone Biosciences, Inc. plans to use its proceeds from a Series A funding to advance its tumor microenvironment-activated therapeutic programs including immune cytokines and bispecific antibodies to the investigational new drug application (IND) enabling stage.
Current Investors
Sinovation Ventures, Co-Win Ventures, Changrong Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Oncology/Cancer Treatment
Website
www.amberstonebio.com
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.